Past Events

February 23, 2021:  Leadership during COVID
    Chris Garabedian, CEO, Xontogeny
    Jodie Morrison, CEO, Cadent Therapeutics
    Ramani Varanasi, President & CEO, X-Biotix Therapeutics
    Moderated by Jennifer Reilly, President & COO, Safety Partners

October 13, 2020:  Fundraising during a Pandemic (part 2)
    Doug Carlson, CFO, Ikena Oncology
    Nilesh Kumar, Partner, Novo Ventures
    Scott Hansen, EVP, Head of Life Sciences, Pacific Western Bank
    Brian Gallagher, Partner, Abingworth

September 24, 2020:  Fundraising during a Pandemic
    Stuart Chaffee, CBO, Praxis Medicines
    Brian Gallagher, Partner, Abingworth
    Keith Dionne, CEO, Casma Therapeutics
    John Gustofson, Managing Director, AbbVie Ventures

February 3, 2020:  Top Considerations when Engaging a Potential Strategic Partnership
    Mary Lynne Hedley, President & COO, Tesaro
    Briane Fenton, CBO, Translate Bio
    Maude Tessier, CBO, Ikena Oncology
    Moderated by Imran Nasrullah, Director, Strategic Partnering, BD & L, Boehringer-Ingelheim

December 2019:  Building your C-Suite
    Stuart Chaffee, CBO, Praxis Medicines
    Michelle Doig, Partner, Omega Funds
    Chris Robinson, Chief Talent Officer, Third Rock Ventures
    Moderated by Keiran English, Partner, Spencer Stuart

October 2019:  The Evolving Role of Artificial Intelligence & Blockchain Technology in Drug Discovery
    Rosana Kapellar, EIR, Google Ventures
    Arthur Hiller, Chief Corporate Development Office, Nuritas
    Bennett Moore, Lead Digital Asset Resource, RSM US
    Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

September 2019:  The Nuts & Bolts of Company Formation
    Paulina Hill, Partner, Omega Funds
    Samantha Truex, CEO, Quench Bio
    Brian Goldstein, Partner, Choate Hall & Stewart
    Scott Hansen, Managing Director, Pacific Western Bank
    Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

May 2019:  Charles River Fever:  Is a Cambridge Address Necessary for Success?
    Robert Urban, Former/Retired Global Head, Johnson & Johnson Innovation, LLC
    Jim Broderick, CEO, Palleon Pharmaceuticals
    Paula Cloghessy, Chief Human Resources Officer, Translate Bio
    Dave Melville, CEO & Founder, The Bowdoin Group
    Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities

March 2019:  Measuring Readiness and Preparing your IPO
    Reenie McCarthy, CEO, Stealth Biotherapeutics
    John Maxwell, CFO, Aquestive Therapeutics
    Gregg Beloff, Managing Director, Danforth Advisors
    Moderated by Greg Schernecke, Partner at Dechert LLP

February 2019:  Company Growth & Evolution of the Board
    Praveen Tipirneni, CEO, Morphic Therapeutics
    Bill Collins, Partner, Life Sciences Practice at Goodwin
    Bruce Rycklik, Managing Partner at Park Square Executive Search
    Moderated by Bruce Ledoux, JP Morgan Securities

December 2018:  Policy, Pricing & Patient Affordability:  A Discussion on Reimbursement
    Amitabh Chandra, Harvard Business School and Harvard Kennedy School of Government
    Jamey Millar, GlaxoSmithKline
    Moderated by Bruce Ledoux, JP Morgan Securities

October 2018:  Patent Strategy & Management: IP Diligence for Companies & Investors & Maximizing Portfolio ROI
    John McDonald, Biogen
    Paul Burgess, Translate Bio
    Karen Sinclair, Harvard University
    Moderated by Andrea Reid, Dechert LLP

September 2018:  The Evolution of Finance
    Steve Robinette, Atlas Ventures
    David Ke, JP Morgan 
    Michal Preminger, J&J Innovation Center
    Brian Goldstein, Choate, Hall & Stewart LLP
    Moderated by Bruce Ledoux, JP Morgan Securities

May 2018:  Structuring of Equity Compensation Models
    Jeb Keiper, Nimbus Therapeutics
    Paula Cloghessy, Translate Bio
    Anne Longmire, JP Morgan Securities
    Ram Kumar, Radford
    Moderated by Bruce Ledoux, JP Morgan Securities

April 2018:  Analysis of Oligonucleotides:  Pros & Cons of Various Analytical Platforms
    David Citerone, Frontage Laboratories
    Jing Li, Alnylam Pharmaceuticals

February 2018:  Tax Reform and its Implications to the Biotech Executive
    Adam Frank, JP Morgan Securities
    Robert McDonald, Partner, RSM
    Moderated by Bruce Ledoux, JP Morgan Securities  

November 2017:  Strategic vs IPO:  A Point & Counterpoint Discussion
    Ron Renaud,  CEO, Translate Bio
    Doug Fambrough, CEO, Dicerna Pharmaceuticals
    Moderated by Bruce Ledoux, JP Morgan Securities

October 2017:  Advances in Biomolecule Analysis:  A CMC Perspective
    X. Sunney Xie- Harvard University
    Desiree Tsao- Momenta Pharmaceuticals
    Min Zhao- Frontage Labs

June 2017:  Maximizing Value in a Merger & Acquisition or IPO Transaction
    Phil Ross, JP Morgan

April 2017:  Approaches to Immunogenicity Validations and the Impact of the Data on Early Clinical Development
    Kevin Carleton- inVentiv Health
    Susan Sloan- Visterra, Inc.

March 2017:  Real World Evidence:  The Convergence of Commercial & Clinical
    David Thompson- inVentiv Health
    Paul Hodgkins- Vertex
    Arthur Hiller- Antyllus Therapeutics
    Bryan Katz- inVentiv Health

December 2016:  Holiday Cocktail Party

November 2016:  Investigations into ISR (Incurred Sample Reproducibility) Failures
    Pierre-Yves Caron- inVentiv Health
    Case Studies presented by Krista Condon (Eisai), Eric David (Biogen), Estela Skende (Sunovion), 
    Heidi Mangus (Agios), and Mark Milton (Novartis)

September 2016:  Regulatory Strategy    
    Carolyn Finkle- inVentiv Health
    Stephane Lamouche- inVentiv Health

June 2016:  Bioanalytical Challenges in Gene & Cellular Therapies and Biotherapeutics
    Lilian Yengi- Bluebird Bio
    Thomas Oglesby- inVentiv Health

May 2016:  Commercial Viability 
    Angus Bromley- inVentiv Health
    Waynne Waterfield- inVentiv Health
    Arthur Hiller- Commercial Strategy Consultant 

March 2016:  Use of Proteomics to Identify Biomarkers
    Richard Lipscombe- Proteomics International
    Ru Wei- Biogen

Sept 2015:  QT Assessments in Early Phase Trials
    Borje Darpo- iCardiac Technologies, Inc
    Sherilyn Adcock- Worldwide Clinical Trials

June 2015:  CRO Selection:  What are you looking for in your CRO Partner?
   Liyu Yang- Biogen
    Jim Vath- Zafgen
    Peter Benton- Worldwide Clinical Trials

March 2015:  Use of Adaptive Protocols in Drug Development
    Jim Gilbert- True North Therapeutics
    Gordon Loewen- Forum Pharmaceuticals
    Darrell Nix- Drug Development Consulting

Sept 2014:  When Novelty is not Enough:  Creating Value Early and Throughout the Development Process
    Mike Murphy- Worldwide Clinical Trials

May 2014:  Use of Radiolabeled Studies in your Development Program
    Wim Tamminga- QPS
    Eric Solon- QPS

Jan 2014:  The New Draft FDA BMV Guidance

September 2013:  Validation of Biomarkers in the Bioanalytical Lab
    Juan Chavez- Biogen
    Jeff Moran- QPS

June 2013:  Development of Bioanalytical Strategies for Characterization of Antibody Drug Conjugates (ADCs)
    Dawn Dufield- Pfizer
    Seema Kumar- Pfizer

March 2013:  Issues with Metabolites
    Caroline Lee- QPS

Jan 2013:  Challenges in Alzheimer's Drug Development
    Manfred Windisch- QPS (formerly JSW Life Sciences)

Oct 2012:  Combining Autoradiography and Bioanalytical Techniques in Drug Discovery
    Grace Poon- Syndexa
    Eric Solon- QPS

June 2012:  Preclinical Data Frontloading: An ADMET Perspective
    Sanjeev Thohan, Novartis
    Jian Yu- QPS

Jan 2012:  New EMA BMV Guidance
    Jeff Moran- QPS

Oct 2011:  Protein analysis by LC-MS/MS
    Joe Palandra- Pfizer
    Ben van Baar- QPS

June 2011: Tissue Bioanalysis
    Stacy Ho - Genzyme
    Zamas Lam - QPS

March 2011: Dry Blood Spot
    Krista Condon - Eisai
    Jaap Weiling - QPS